Ultragenyx Pharmaceutical Liabilities 2024

Ultragenyx Pharmaceutical Aktienanalyse

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that focuses on developing therapies for rare diseases. The company was founded in 2010 and is headquartered in Novato, California. The history of Ultragenyx began when the founder and CEO Emil Kakkis recognized the lack of medications for rare diseases. These diseases often affect a very small number of patients and there are few or no established treatment options. Ultragenyx decided to fill this gap and has been working since its inception to find new ways to develop therapies for rare diseases. The company's business model is based on utilizing innovative approaches to develop therapies for rare diseases and building close relationships with patient communities. Ultragenyx is divided into different divisions to address various disease areas. The largest division focuses on developing therapies for lysosomal storage diseases. These are a group of rare, inherited diseases caused by a deficiency of enzymes needed for the proper functioning of lysosomes in the body. Ultragenyx has developed several products in the field of lysosomal storage diseases, including an enzyme replacement therapy for the treatment of mucopolysaccharidosis VII, a rare metabolic disorder caused by a deficiency of the enzyme beta-glucuronidase. The company has also developed an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI. Another division of Ultragenyx focuses on developing therapies for genetically inherited metabolic disorders. These diseases are caused by mutations in genes that are responsible for important metabolic processes in the body. Ultragenyx has several drugs in the pipeline that focus on the treatment of genetically inherited metabolic disorders. Ultragenyx also has a division that focuses on the treatment of central nervous system (CNS) diseases. The company is working on therapies for various rare neurological disorders, including X-linked adrenoleukodystrophy and glycogen storage disease type II. Ultragenyx has developed flexible development platforms to quickly respond to the needs of patients with rare diseases. The company works closely with patient communities to receive feedback on medications and development plans. This helps the company to quickly address patient concerns and requirements and develop better therapies. Overall, Ultragenyx Pharmaceutical Inc. has a clear vision that is attributed to its business model and innovation culture. The company is committed to developing therapies for people with rare diseases that contribute to improving their quality of life. Ultragenyx has an impressive pipeline of drugs and is well positioned to continue to grow in the future and develop innovative therapies for rare diseases. Ultragenyx Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ultragenyx Pharmaceutical's Liabilities

Ultragenyx Pharmaceutical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ultragenyx Pharmaceutical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ultragenyx Pharmaceutical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ultragenyx Pharmaceutical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ultragenyx Pharmaceutical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ultragenyx Pharmaceutical stock

What is the level of liabilities of Ultragenyx Pharmaceutical this year?

Ultragenyx Pharmaceutical has a debt balance of 1.22 B USD this year.

What were the liabilities of Ultragenyx Pharmaceutical compared to the previous year?

The liabilities of Ultragenyx Pharmaceutical have increased by 1.89% increased compared to the previous year.

What are the consequences of high debt for investors of Ultragenyx Pharmaceutical?

High liabilities can pose a risk for investors of Ultragenyx Pharmaceutical, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ultragenyx Pharmaceutical?

Low liabilities mean that Ultragenyx Pharmaceutical has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ultragenyx Pharmaceutical affect the company?

An increase in liabilities of Ultragenyx Pharmaceutical can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ultragenyx Pharmaceutical affect the company?

A decrease in the liabilities of Ultragenyx Pharmaceutical can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ultragenyx Pharmaceutical?

Some factors that can influence the liabilities of Ultragenyx Pharmaceutical include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ultragenyx Pharmaceutical so important for investors?

The liabilities of Ultragenyx Pharmaceutical are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ultragenyx Pharmaceutical take to modify the liabilities?

To change its liabilities, Ultragenyx Pharmaceutical can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ultragenyx Pharmaceutical pay?

Over the past 12 months, Ultragenyx Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ultragenyx Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Ultragenyx Pharmaceutical?

The current dividend yield of Ultragenyx Pharmaceutical is .

When does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Ultragenyx Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ultragenyx Pharmaceutical located?

Ultragenyx Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ultragenyx Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ultragenyx Pharmaceutical from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Ultragenyx Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Ultragenyx Pharmaceutical in the year 2023?

In the year 2023, Ultragenyx Pharmaceutical distributed 0 USD as dividends.

In which currency does Ultragenyx Pharmaceutical pay out the dividend?

The dividends of Ultragenyx Pharmaceutical are distributed in USD.